How Investors Are Reacting To Abbott (ABT) Expanding Lingo CGM And Nutrition Data For Metabolic Health

• In early December 2025, Abbott announced that its Lingo over-the-counter continuous glucose monitor became available for Android users, while new real-world data linked both Lingo and Ensure Max Protein shakes to improved glucose control and metabolic health, particularly in people with obesity.
• This combination of broader device access and data-backed nutrition benefits underscores how Abbott is connecting its medical devices and nutrition portfolios to everyday health habits, potentially deepening customer engagement across multiple product lines.
• We’ll now examine how Lingo’s expanded Android availability, and its data showing links between protein intake and glucose control, influence Abbott’s investment narrative.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

Abbott Laboratories Investment Narrative Recap

To own Abbott, you need to believe its diversified mix of devices, diagnostics, nutrition and generics can offset pressure in areas like COVID-related diagnostics and CGM pricing. The Lingo Android launch and protein data reinforce Abbott’s diabetes and metabolic health ecosystem, but do not materially change the nearest term swing factor, which remains how quickly diagnostic headwinds from COVID testing declines and China volume-based procurement ease or stabilize.

The most relevant recent announcement here is Abbott’s reaffirmed 2025 organic sales growth guidance of 7.5% to 8.0% excluding COVID testing. That guidance frames how investors might view Lingo’s Android expansion and the Ensure Max Protein data: as incremental support for the longer term chronic disease and aging demographics catalyst, rather than a single quarter needle-mover.

Yet even as Lingo expands and supports Abbott’s diabetes ecosystem, investors should still watch the risk that aggressive US competitive bidding in CGM could...

Read the full narrative on Abbott Laboratories (it's free!)

Abbott Laboratories’ narrative projects $53.3 billion revenue and $9.4 billion earnings by 2028.

Uncover how Abbott Laboratories' forecasts yield a $144.43 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Eleven members of the Simply Wall St Community see fair value for Abbott anywhere between US$73 and US$144, underlining how far opinions can spread. Against that backdrop, the chronic disease and aging population theme that supports Abbott’s devices and nutrition segments may be a key lens for you to compare these differing views.

Explore 11 other fair value estimates on Abbott Laboratories - why the stock might be worth 40% less than the current price!

Build Your Own Abbott Laboratories Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Find companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com